User: Guest  Login
Title:

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.

Document type:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
Author(s):
Arnold, D; Höhler, T; Dittrich, C; Lordick, F; Seufferlein, T; Riemann, J; Wöll, E; Herrmann, T; Zubel, A; Schmoll, HJ
Abstract:
BACKGROUND: This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer. PATIENTS AND METHODS: Cetuximab was administered weekly: 400 mg/m(2) initial dose, then 250 mg/m(2) and FUFOX: oxaliplatin 50 mg/m(2), FA 500 mg/m(2) and 5-FU...     »
Journal title abbreviation:
Ann Oncol
Year:
2008
Journal volume:
19
Journal issue:
8
Pages contribution:
1442-9
Language:
eng
Fulltext / DOI:
doi:10.1093/annonc/mdn150
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/18441330
Print-ISSN:
0923-7534
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX